Effects of darbepoetin alfa and epoetin beta pegol on iron kinetics in hemodialysis patients

被引：0

作者：

Sawa J. ^{[1
]}

Inaba M. ^{[2
,3
]}

Noguchi K. ^{[1
]}

Nakagawa C. ^{[1
]}

Kuwamura M. ^{[1
]}

Kuwamura Y. ^{[1
]}

Wada N. ^{[1
]}

Kitatani K. ^{[1
]}

Kawaguchi Y. ^{[1
]}

Kumeda Y. ^{[1
]}

机构：

[1] Department of Internal Medicine, Minami-Osaka Hospital, Osaka

[2] Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine Osaka, Osaka

[3] Department of Nephrology, Osaka City University Graduate School of Medicine Osaka, Osaka

来源：

Renal Replacement Therapy | / 2卷 / 1期

关键词：

Darbepoetin alfa; Epoetin beta pegol; Ferritin; Hemodialysis; Hemoglobin; Hepcidin; Iron utilization; Transferrin saturation;

D O I：

10.1186/s41100-016-0037-z

中图分类号：

学科分类号：

摘要：

Background: Erythropoiesis-stimulating agents, for example epoetin beta pegol which is a continuous erythropoietin receptor activator (CERA), and darbepoetin alfa (DPO), are recently introduced into clinical practice for the treatment of anemia in hemodialysis patients. Here, we compared the effects of CERA and DPO on erythropoiesis and iron kinetics in hemodialysis patients. Methods: In this open label, single arm trial, after 40 μg/week of DPO administration, 75 μg/2 weeks of CERA was administered during 14 days in 7 hemodialysis patients without clinically overt inflammation or infection. Serum parameters of erythropoietic activity (hemoglobin) and iron kinetics (hepcidin-25 [hepcidin], ferritin, high-sensitivity C-reactive protein and transferrin saturation [TSAT]) were evaluated during the study periods. Results: DPO significantly increased the hemoglobin levels above the baseline, as compared to the insignificant increase by CERA. Suppression of serum ferritin was more significant during CERA than DPO (P = 0.018), while TSAT or serum hepcidin did not differ significantly between CERA and DPO (TSAT, P = 0.866; hepcidin, P = 0.063). Our results suggested that, under conditions indicating a significantly weaker effect of CERA than DPO on erythroblastosis, the greater suppression of serum ferritin by CERA might indicate its potent effect on iron utilization. Conclusions: The effect of CERA administered once every 2 weeks exhibited no less potent effect in terms of iron utilization than that of DPO administered every week. © 2016 The Author(s).

引用

共 27 条

[1]

Macdougall I.C., Eckardt K.U., Novel strategies for stimulating erythropoiesis and potential new treatments for anemia, Lancet, 368, pp. 947-953, (2006)

[2]

Brunkhosrst R., Bommer J., Et al., Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients, Nephrol Dial Transplant, 19, pp. 1224-1230, (2004)

[3]

Levin N.W., Fishbane S., Canedo F.V., Zeig S., Nassar G.M., Moran J.E., Villa G., Beyer U., Oguey D., Intravenous methoxy polyethylene glycol-epoetin beta for hemoglobin control in patients with chronic kidney disease who are on dialysis: A randomized non-inferiority trial (MAXIMA), Lancet, 370, pp. 1415-1421, (2007)

[4]

Canaud B., Mingardi G., Braun J., Aljama P., Kerr P.G., Locatelli F., Villa G., Van Vlem B., McMahon A.W., Kerloeguen C., Beyer U., Intravenous C.E.R.A. maintains stable hemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study, Nephrol Dial Transplant, 23, pp. 3654-3661, (2008)

[5]

Shoji S., Inaba M., Tomosugi N., Et al., Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients, Eur J Hematol, 90, pp. 237-244, (2013)

[6]

Tsubakihara Y., Nishi S., Akiba T., Et al., 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease, Ther Apher Dial, 14, 3, pp. 240-275, (2010)

[7]

Sasaki Y., Noguchi-Sasaki M., Yasuno H., Yorozu K., Shimonaka Y., Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice, Int J Hematol, 96, pp. 692-700, (2012)

[8]

Kautz L., Jung G., Valore E.V., Rivella S., Ganz T., Identification of erythroferrone as an erythroid regulator of iron metabolism, Nat Genet, 46, 7, pp. 678-684, (2014)

[9]

Murano N., Ishigai M., Yasuno H., Shimonaka Y., Aso Y., Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction mass spectrometry coupled with trichloroacetic acid clean-up, Rapid Commun Mass Spectrom, 21, pp. 4033-4038, (2007)

[10]

Maekawa K., Shoji T., Emoto M., Okuno S., Yamakawa T., Ishimura E., Inaba M., Nishizawa Y., Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients, Nephrol Dial Transplant, 23, pp. 2329-2336, (2008)

← 1 2 3 →